SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "AMNE:(MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi) "

Sökning: AMNE:(MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
12891.
12892.
  • Zheng, Huili, et al. (författare)
  • Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus
  • 2004
  • Ingår i: Journal of Steroid Biochemistry and Molecular Biology. - Elsevier. - 1879-1220. ; 88:2, s. 143-156
  • Tidskriftsartikel (refereegranskat)abstract
    • To investigate the differential short-term effects of selective estrogen receptor (ER) modulators (SERMs) on uterus, we treated adult ovariectomized rats with a novel SERM, ospemifene (Osp), two previously established SERMs (tamoxifen and raloxifene (Ral)) and estradiol. The expression of two estrogen-regulated early response genes c-fos and vascular endothelial growth factor (VEGF), and DNA synthesis were analysed at 1-24 h after treatment of ovariectomized rats. Induction of c-fos mRNA by each of the SERMs showed a biphasic pattern with peaks at 3 and 20 h, respectively. The maximum level of VEGF mRNA was observed at 1 h after raloxifene and 6 h after tamoxifen or ospemifene treatment. Maximum levels of the c-fos and VEGF mRNA after raloxifene treatment were higher than those seen after treatments with E2 or a corresponding dose of tamoxifen or ospemifene. DNA synthesis was significantly increased by ospemifene, tamoxifen and raloxifene both in luminal and glandular epithelium. The stimulation was transient, peaking at 16 h. In comparison, the maximum level observed at 16h after E2 treatment sustained at least until 24 h. DNA synthesis in stromal cells was increased by the SERMs but not by E2 at 24 h. When treated together with E2, the SERMs were able to antagonise E2-stimulated DNA synthesis at 16 h. Our results demonstrate that the initial response of uterus to ospemifene, raloxifene and tamoxifen includes activation of early response genes and even transient stimulation of DNA synthesis in spite of their different long-term effects. However, the early stimulatory events may be mediated by different mechanisms leading to diverging pathways in various tissue compartments and development of differential SERM-specific long-term responses of uterus.
  •  
12893.
  • Zhou, K., et al. (författare)
  • Radiation induces progenitor cell death, microglia activation, and blood-brain barrier damage in the juvenile rat cerebellum
  • 2017
  • Ingår i: Scientific Reports. - 2045-2322. ; 7
  • Tidskriftsartikel (refereegranskat)abstract
    • Posterior fossa tumors are the most common childhood intracranial tumors, and radiotherapy is one of the most effective treatments. However, irradiation induces long-term adverse effects that can have significant negative impacts on the patient's quality of life. The purpose of this study was to characterize irradiation-induced cellular and molecular changes in the cerebellum. We found that irradiation-induced cell death occurred mainly in the external germinal layer (EGL) of the juvenile rat cerebellum. The number of proliferating cells in the EGL decreased, and 82.9% of them died within 24 h after irradiation. Furthermore, irradiation induced oxidative stress, microglia accumulation, and inflammation in the cerebellum. Interestingly, blood-brain barrier damage and blood flow reduction was considerably more pronounced in the cerebellum compared to other brain regions. The cerebellar volume decreased by 39% and the migration of proliferating cells to the internal granule layer decreased by 87.5% at 16 weeks after irradiation. In the light of recent studies demonstrating that the cerebellum is important not only for motor functions, but also for cognition, and since treatment of posterior fossa tumors in children typically results in debilitating cognitive deficits, this differential susceptibility of the cerebellum to irradiation should be taken into consideration for future protective strategies.
  •  
12894.
  • Zhou, Qimin, et al. (författare)
  • YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling
  • 2020
  • Ingår i: Journal of Translational Medicine. - BioMed Central (BMC). - 1479-5876. ; 18, s. 1-10
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Pancreatic cancer is a major cause of cancer-related mortality. The identification of effective biomarkers is essential in order to improve management of the disease. Yes-associated protein 1 (YAP1) is a downstream effector of the Hippo pathway, a signal transduction system implicated in tissue repair and regeneration, as well as tumorigenesis. Here we evaluate the biomarker potential of YAP1 in pancreatic cancer tissue.METHODS: YAP1 was selected as a possible biomarker for pancreatic cancer from global protein sequencing of fresh frozen pancreatic cancer tissue samples and normal pancreas controls. The prognostic utility of YAP1 was evaluated using mRNA expression data from 176 pancreatic cancer patients in The Cancer Genome Atlas (TCGA), as well as protein expression data from immunohistochemistry analysis of a local tissue microarray (TMA) cohort comprising 140 pancreatic cancer patients. Ingenuity Pathway Analysis was applied to outline the interaction network for YAP1 in connection to the pancreatic tumor microenvironment. The expression of YAP1 target gene products was evaluated after treatment of the pancreatic cancer cell line Panc-1 with three substances interrupting YAP-TEAD interaction, including Super-TDU, Verteporfin and CA3.RESULTS: Mass spectrometry based proteomics showed that YAP1 is the top upregulated protein in pancreatic cancer tissue when compared to normal controls (log2 fold change 6.4; p = 5E-06). Prognostic analysis of YAP1 demonstrated a significant correlation between mRNA expression level data and reduced overall survival (p = 0.001). In addition, TMA and immunohistochemistry analysis suggested that YAP1 protein expression is an independent predictor of poor overall survival [hazard ratio (HR) 1.870, 95% confidence interval (CI) 1.224-2.855, p = 0.004], as well as reduced disease-free survival (HR 1.950, 95% CI 1.299-2.927, p = 0.001). Bioinformatic analyses coupled with in vitro assays indicated that YAP1 is involved in the transcriptional control of target genes, associated with extracellular matrix remodeling, which could be modified by selected substances disrupting the YAP1-TEAD interaction.CONCLUSIONS: Our findings indicate that YAP1 is an important prognostic biomarker for pancreatic cancer and may play a regulatory role in the remodeling of the extracellular matrix.
12895.
  • Zhou, Wenjing, et al. (författare)
  • A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ.
  • 2013
  • Ingår i: International Journal of Breast Cancer. - Hindawi Publishing Corporation. - 2090-3170. ; 2013
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction. About half of all new ipsilateral events after a primary ductal carcinoma in situ (DCIS) are invasive carcinoma. We studied tumor markers in the primary DCIS in relation to type of event (invasive versus in situ). Methods. Two hundred and sixty-six women with a primary DCIS from two source populations, all with a known ipsilateral event, were included. All new events were regarded as recurrences. Patient and primary tumor characteristics (estrogen receptor (ER), progesterone receptor (PR), HER2, EGFR, and Ki67) were evaluated. Logistic regression was used to calculate odd ratios and 95% confidence intervals in univariate and multivariate analyses. Results. One hundred and thirty-six of the recurrences were invasive carcinoma and 130 were in situ. The recurrence was more often invasive if the primary DCIS was ER+ (OR 2.5, 95% CI 1.2-5.1). Primary DCIS being HER2+ (OR 0.5, 95% CI 0.3-0.9), EGFR+ (OR 0.4, 95% CI 0.2-0.9), and ER95-/HER2+ (OR 0.2, 95% CI 0.1-0.6) had a lower risk of a recurrence being invasive. Conclusions. In this study, comparing type of recurrence after a DCIS showed that the ER-/HER2+ tumors were related to a recurrence being a new DCIS. And surprisingly, tumors being ER+, HER2-, and EGFR- were related to a recurrence being invasive cancer.
12896.
  • Zhou, Wenjing, 1979-, et al. (författare)
  • Breast carcinoma with neoductgenesis : a new subgroup of breast cancer
  • ????
  • Annan publikation (övrigt vetenskapligt)abstract
    • <p>Background: A new subgroup of breast cancer has been proposed: breast carcinoma with neoductgenesis. Cases presenting with casting type calcifications on the mammogram, histologically high grade DCIS with an abnormal number of ducts, periductal desmoplastic reaction and lymphocyte infiltration has been suggested to represent a more aggressive form of breast cancer. Treatment decision based on traditional histopathology showing DCIS might be challenged if neoductgenesis is diagnosed. We evaluated a histological classification system proposed for neoductgenesis and studied tumor biology in cases with and without neoductgenesis.</p> <p> </p> <p>Material and Method: Seventy-four tumors with DCIS grade 2-3, with or without an invasive component, were blocked in TMAs. A classification system based on a pathological evaluation and Tenascin-C (Tn-C) expression was used to categorize tumors as showing neoductgenesis or not. Immunohistochemical staining for known tumor markers and correlation with mammographic features was performed. Logistic regression model was use to evaluate the correlation between breast carcinoma with neoductgenesis and molecular- and mammographic features.</p> <p> </p> <p>Results: Four pathologists could categorize cases as “possible neoductgenesis” with an overall correlation of 72% and a kappa value of 0.44. Adding Tn-C staining resulted in a group with neoductgenesis (n=37) and one without (n=31). Neoductgenesis correlated significantly with mammographic casting- and crushed stone microcalcifications and estrogen receptor status (p-values 0.04 and 0.03, respectively). High nuclear grade, HER2 positivity, progesterone receptor negativity and high proliferation were also more often seen in the group with neoductgenesis, but this was not statistically significant (0.10, 0.07, 0.20 and 0.29).</p> <p> </p> <p>Discussion: We developed reproducible histologic criteria for a new entity: breast carcinoma with neoductgenesis. The system seemed to be useful in receiving reproducibility between pathologists making the diagnosis. Neoductgenesis was related to more aggressive tumor biology and to the mammographic features. Our findings have to be repeated and the relation to prognosis further studied. However, we can already predict a potential benefit for women earlier considered having a pure DCIS but now diagnosed as breast carcinoma with neoductgenesis and a need to develop appropriate treatment regiments.</p>
  •  
12897.
  • Zhou, Wenjing, et al. (författare)
  • Ductal Breast Carcinoma In Situ Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort
  • 2017
  • Ingår i: International Journal of Breast Cancer. - Hindawi Publishing Corporation. - 2090-3170 .- 2090-3189.
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Casting-type calcifications and a histopathological picture with cancer-filled duct-like structures have been presented as breast cancer with neoductgenesis. We correlated mammographic features and histopathological neoductgenesis with prognosis in a DCIS cohort with long follow-up. Mammographic features were classified into seven groups according to Tabar. Histopathological neoductgenesis was defined by concentration of ducts, lymphocyte infiltration, and periductal fibrosis. Endpoints were ipsilateral (IBE) in situ and invasive events. Casting-type calcifications and neoductgenesis were both related to high nuclear grade, ER-and PR-negativity, and HER2 overexpression but not to each other. Casting-type calcifications and neoductgenesis were both related to a nonsignificant lower risk of invasive IBE, HR 0.38 (0.13-1.08) and 0.82 (0.29-2.27), respectively, and the HR of an in situ IBE was 0.90 (0.41-1.95) and 1.60 (0.75-3.39), respectively. Casting-type calcifications could not be related to a worse prognosis in DCIS. We cannot explain why a more aggressive phenotype of DCIS did not correspond to a worse prognosis. Further studies on how the progression from in situ to invasive carcinoma is driven are needed.</p>
  •  
12898.
  • Zhou, Wenjing, et al. (författare)
  • Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study
  • 2010
  • Ingår i: BMC Cancer. - BioMed Central (BMC). - 1471-2407. ; 10
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Microarray gene-profiling of invasive breast cancer has identified different subtypes including luminal A, luminal B, HER2-overexpressing and basal-like groups. Basal-like invasive breast cancer is associated with a worse prognosis. However, the prognosis of basal-like ductal carcinoma in situ (DCIS) is still unknown. Our aim was to study the prognosis of basal-like DCIS in a large population-based cohort. Methods: All 458 women with a primary DCIS diagnosed between 1986 and 2004, in Uppland and Vastmanland, Sweden were included. TMA blocks were constructed. To classify the DCIS tumors, we used immunohistochemical (IHC) markers (estrogen-, progesterone-, HER2, cytokeratin 5/6 and epidermal growth factor receptor) as a surrogate for the gene expression profiling. The association with prognosis was examined for basal-like DCIS and other subtypes using Kaplan-Meier survival analyses and Cox proportional hazards regression models. Results: IHC data were complete for 392 women. Thirty-two were basal-like (8.2%), 351 were luminal or HER2-positive (89.5%) and 9 unclassified (2.3%). Seventy-six women had a local recurrence of which 34 were invasive. Another 3 women had general metastases as first event. Basal-like DCIS showed a higher risk of local recurrence and invasive recurrence 1.8 (Confidence interval (CI) 95%, 0.8-4.2) and 1.9 (0.7-5.1), respectively. However, the difference was not statistically significant. Also, no statistically significant increased risk was seen for triple-negative or high grade DCIS. Conclusions: Basal-like DCIS showed about a doubled, however not statistically significant risk for local recurrence and developing invasive cancer compared with the other molecular subtypes. Molecular subtyping was a better prognostic parameter than histopathological grade.
12899.
  • Zhou, Wenjing, et al. (författare)
  • Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study
  • 2013
  • Ingår i: BMC Cancer. - BioMed Central (BMC). - 1471-2407. ; 13
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Different molecular subtypes of breast cancer have been identified based on gene expression profiling. Treatment suggestions based on an approximation of these subtypes by immunohistochemical criteria have been published by the St Gallen international expert consensus panel. Ductal carcinoma in situ (DCIS) can be classified into the same molecular subtypes. Our aim was to study the relation between these newly defined subtypes and prognosis in DCIS. Methods: TMA including 458 women from a population-based cohort with DCIS diagnosed 1986-2004 was used. Stainings for ER, PR, HER2 and Ki67 were used to classify the surrogate molecular subtypes according to the St Gallen criteria from 2011. The associations with prognosis were examined using Kaplan-Meier analyses and Cox proportional hazards regression models. Results: Surrogate molecular subtyping could be done in 381 cases. Mean follow up was 164 months. Of the classified DCIS 186 were Luminal A (48.8%), 33 Luminal B/HER2-(8.7%), 74 Luminal B/HER2+ (17.4%), 61 HER2+/ER-(16.0%) and 27 Triple Negative (7.1%). One hundred and two women had a local recurrence of which 58 were invasive. Twenty-two women had generalised disease, 8 without a prior local recurrence. We could not find a prognostic significance of the molecular subtypes other than a higher risk of developing breast cancer after more than 10 years of follow-up among women with a Triple Negative DCIS (OR 3.2; 95% CI 1.1-9.8). Conclusions: The results from this large population-based cohort, with long-term follow up failed to demonstrate a prognostic value for the surrogate molecular subtyping of DCIS using the St Gallen criteria up to ten years after diagnosis. More than ten years after diagnosis Triple Negative DCIS had an elevated risk of recurrence.
12900.
  • Zhou, Wenjing, et al. (författare)
  • Tumor Markers Predicting Type of Recurrence after a Primary Ductal Carcinoma <em>In Situ</em>
  • 2012
  • Ingår i: Breast Cancer Research. - 1465-5411 .- 1465-542X.
  • Tidskriftsartikel (övrigt vetenskapligt)abstract
    • <p><strong>Introduction: </strong></p> <p>About half of all recurrences after a primary ductal carcinoma <em>in situ</em> (DCIS) are invasive. The determinants for type of recurrence, in situ or invasive, are not known. We studied markers in primary DCIS in relation to type of recurrence.</p> <p><strong>Methods:</strong></p> <p>Two hundred and sixty six primary DCIS with a known recurrence were included. One hundred were from a population based cohort with 458 women diagnosed 1986-2004 in Uppland/Västmanland region, Sweden, and all 166 women with a recurrence from the randomized nationwide SweDCIS Trial (1987-1999). The 358 women without a recurrence were used as a reference group. TMA-blocks were constructed and estrogen receptor- (ER), progesterone receptor- (PR), HER2, EGFR, cytokeratin 5/6, Ki67, FOXA1, FOXC1, GATA-3 and CD10 status were evaluated in the primary tumors. Logistic regression was used to calculate odd ratios and 95% confidence intervals in univariate and multivariate analyses (adjusted for age, free margin, surgical method and molecular subtype).</p> <p><strong>Results:</strong></p> <p>One hundred and thirty of the recurrences were <em>in situ</em> and 136 invasive. In multivariate analyses, a recurrence was more often invasive if the primary was ER positive (OR 2.5, CI 95 1.2 – 5.1). Primaries being HER2 positive (OR 0.5, CI 95 0.3-0.9), EGFR positive (OR 0.4, CI 95 0.2-0.9) and ER-/HER2+ (OR 0.2, CI 95 0.1-0.6) had a lower risk of the recurrence being invasive. Primaries of the molecular subtype ER+/HER2+ had higher risk of any recurrence (OR 1.9, CI 95 1.1-3.4) as did primaries expressing FOXA1 (OR 3.1, CI 95 1.5-6.2) and FOXC1 (OR 2.9, CI 95 1.7-5.0).</p> <p><strong>Conclusions:</strong></p> <p>Surprisingly, recurrences after an ER-/HER2+, ER negative or EGFR positive primary DCIS were more often of the <em>in situ type</em>. The molecular subtype ER+/HER2+, FOXA1 positivity and FOXC1 positivity were risk factors for any recurrence.</p>
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (3205)
Typ av publikation
tidskriftsartikel (11149)
doktorsavhandling (559)
forskningsöversikt (479)
konferensbidrag (469)
annan publikation (150)
bokkapitel (114)
visa fler...
rapport (18)
bok (12)
samlingsverk (redaktörskap) (7)
licentiatavhandling (4)
recension (3)
proceedings (redaktörskap) (1)
patent (1)
visa färre...
Typ av innehåll
refereegranskat (11365)
övrigt vetenskapligt (2203)
populärvet., debatt m.m. (27)
Författare/redaktör
Trichopoulou, Antoni ... (424)
Riboli, Elio (418)
Tumino, Rosario (395)
Overvad, Kim (389)
Boeing, Heiner (373)
Khaw, Kay-Tee (350)
visa fler...
Olsson, Håkan, (349)
Kaaks, Rudolf (342)
Palli, Domenico (292)
Weiderpass, Elisabet ... (287)
Jirström, Karin, (281)
Boutron-Ruault, Mari ... (277)
Borg, Åke, (270)
Manjer, Jonas, (269)
Tjonneland, Anne (259)
Hemminki, Kari, (252)
Bueno-de-Mesquita, H ... (240)
Panico, Salvatore (239)
Stattin, Pär, (229)
Vineis, Paolo (228)
Sanchez, Maria-Jose (223)
Glimelius, Bengt, (204)
Trichopoulos, Dimitr ... (200)
Travis, Ruth C (198)
Trichopoulou, A (197)
Riboli, E (196)
Fernö, Mårten, (189)
Tumino, R (186)
Overvad, K (185)
Barricarte, Aurelio (185)
Ardanaz, Eva (184)
Tjonneland, A (183)
Tjønneland, Anne (182)
Clavel-Chapelon, Fra ... (178)
Steineck, G, (177)
Dasu, Alexandru (176)
Boeing, H (171)
Peeters, Petra H. (169)
Kaaks, R (169)
Forssell-Aronsson, E ... (167)
Lagiou, Pagona (164)
Jenab, Mazda (164)
Dorronsoro, Miren (162)
Henriksson, Roger, (162)
Toma-Dasu, Iuliana, (162)
Bendahl, Pär Ola, (161)
Peeters, Petra H M (158)
Sacerdote, Carlotta (157)
Steineck, Gunnar, 19 ... (157)
Weiderpass, E, (155)
visa färre...
Lärosäte
Lunds universitet (5717)
Göteborgs universitet (2204)
Uppsala universitet (1840)
Umeå universitet (1751)
Karolinska Institutet (1653)
Örebro universitet (518)
visa fler...
Linköpings universitet (467)
Stockholms universitet (203)
Chalmers tekniska högskola (163)
Kungliga Tekniska Högskolan (85)
Högskolan i Jönköping (63)
Högskolan i Skövde (34)
Sveriges Lantbruksuniversitet (33)
Linnéuniversitetet (28)
Sophiahemmet Högskola (12)
Mittuniversitetet (10)
Gymnastik- och idrottshögskolan (10)
Ersta Sköndal Bräcke högskola (10)
Röda Korsets Högskola (10)
Högskolan i Borås (9)
Högskolan Väst (8)
Högskolan Kristianstad (6)
swepub_uni:mau_t (6)
Södertörns högskola (6)
Högskolan i Gävle (6)
Karlstads universitet (4)
Högskolan i Halmstad (3)
Blekinge Tekniska Högskola (3)
Mälardalens högskola (1)
RISE (1)
Försvarshögskolan (1)
Högskolan Dalarna (1)
visa färre...
Språk
Engelska (12545)
Svenska (148)
Danska (3)
Spanska (3)
Isländska (3)
Annat språk (3)
visa fler...
Norska (2)
Tyska (1)
Odefinierat språk (1)
Polska (1)
Kinesiska (1)
Ukrainska (1)
visa färre...
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (12966)
Naturvetenskap (316)
Samhällsvetenskap (103)
Teknik (63)
Lantbruksvetenskap (19)
Humaniora (16)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy